Zolbetuximab (IMAB-362) is a chimeric monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tight junction protein isoform. It is approved and indicated for the treatment of CLDN18.2-positive, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. As an IgG1 antibody, it induces tumor cell death primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).